Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration | Zendy

Brigitte Meyer | Zendy; Gabriela Kornek | Zendy; Mariam Nikfardjam | Zendy; Georg Delle Karth | Zendy; Gottfried Heinz | Zendy; Gottfried J. Locker | Zendy; Walter Jaeger | Zendy; Florian Thalhammer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration

Author(s) -

Brigitte Meyer,

Gabriela Kornek,

Mariam Nikfardjam,

Georg Delle Karth,

Gottfried Heinz,

Gottfried J. Locker,

Walter Jaeger,

Florian Thalhammer

Publication year - 2005

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dki133

Subject(s) - linezolid , medicine , pharmacokinetics , vancomycin , streptococcus pneumoniae , dosing , renal function , anesthesia , hemofiltration , antibiotics , surgery , pharmacology , staphylococcus aureus , hemodialysis , chemistry , biochemistry , biology , bacteria , genetics

Linezolid is a new antibacterial agent with a broad spectrum of activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., and penicillin-resistant Streptococcus pneumoniae. The aim of this prospective, single-centre, open-label, two-arm study was to investigate the pharmacokinetics of linezolid during continuous venovenous haemofiltration (CVVH) in critically ill patients and to derive a dosage recommendation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research